EUVIMEDEUVIMED entdecken
Crossref

Hop-derived Humulinones Reveal Protective Effects in in vitro Models of Hepatic Steatosis, Inflammation and Fibrosis

Abdo Mahli, Wolfgang E Thasler, Martin Biendl, Claus Hellerbrand

Planta Medica · 01.10.2023 · 89 (12) · 1138-1146

DOI: 10.1055/a-2103-3230 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Planta Medica, erschienen am 01.10.2023. Verfasst von Abdo Mahli und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biochemistry, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nonalcoholic fatty liver disease (NAFLD) is emerging as leading cause of liver disease worldwide. Specific pharmacologic therapy for NAFLD is a major unmet medical need. Recently, iso-alpha acids, hop-derived bitter compounds in beer, have been shown to beneficially affect NAFLD pathology. Humulinones are further hop derived bitter acids particularly found in modern styles of beer. So far, biological effects of humulinones have been unknown. Here, we investigated the effect of humulinones in in vitro models for hepatic steatosis, inflammation and fibrosis. Humulinones dose-dependently inhibited fatty acid induced lipid accumulation in primary human hepatocytes. Humulinones reduced the expression of fatty acid uptake transporter CD36 and key enzymes of (de novo) lipid synthesis. Conversely, humulinones increased the expression of FABP1, CPT1 and ACOX1, indicative for increased lipid combustion. Furthermore, humulinones ameliorated steatosis induced pro-inflammatory gene expression. Furthermore, humulinones significantly reduced the expression of pro-inflammatory and pro-fibrogenic factors in control as well as lipopolysaccharide treated activated hepatic stellate cells, which play a key role in hepatic fibrosis. In conclusion, humulinones beneficially affect different pathophysiological steps of NAFLD. Our data suggest humulinones as promising therapeutic agents for the prevention and treatment of NAFLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseHumansInflammationHepatocytesLiver CirrhosisFatty AcidsLiver

Substanzen

Fatty Acids

Autor:innen und Institutionen

  • Institute of Biochemistry, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
  • Department of Pharmacology and Biomedical Sciences, Faculty of Pharmacy and Medical Sciences, University of Petra, Amman, Jordan.
  • Human Tissue and Cell Research-Services GmbH, Planegg/Martinsried, Germany.
  • Hopsteiner, Hallertauer Hopfenveredelung GmbH, Mainburg, Germany.

Zitieren

APA

Mahli, A., Thasler, W. E., Biendl, M., & Hellerbrand, C. (2023). Hop-derived Humulinones Reveal Protective Effects in in vitro Models of Hepatic Steatosis, Inflammation and Fibrosis. Planta Medica, 89(12), 1138-1146. https://doi.org/10.1055/a-2103-3230

Vancouver

Mahli A, Thasler WE, Biendl M, Hellerbrand C. Hop-derived Humulinones Reveal Protective Effects in in vitro Models of Hepatic Steatosis, Inflammation and Fibrosis. Planta Medica. 2023;89(12):1138-1146. doi:10.1055/a-2103-3230

BibTeX
@article{Mahli2023,
  author = {Mahli, Abdo and Thasler, Wolfgang E and Biendl, Martin and Hellerbrand, Claus},
  title = {Hop-derived Humulinones Reveal Protective Effects in in vitro Models of Hepatic Steatosis, Inflammation and Fibrosis},
  journal = {Planta Medica},
  year = {2023},
  volume = {89},
  number = {12},
  pages = {1138--1146},
  doi = {10.1055/a-2103-3230}
}
Kostenlos starten →